Announcement of TTY Biopharm's unaudited income information in December 2025
2026.1.16
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2026/01/16 | Time of announcement | 15:44:29 |
| Subject | Announcement of TTY Biopharm's unaudited income information in December 2025 | ||||
| Date of events | 2026/01/16 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2026/01/16 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $641,547 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $148,741 thousands, and a consolidated income before tax of $185,935 thousands in December 2025; net income attributed to stockholders of the company was $119,301 thousands; EPS is $0.48. Year-to-date consolidated net sales was $6,452,948 thousands (in NT dollars; unaudited), a consolidated operating profit was $1,704,883 thousands and consolidated income before tax was $2,119,936 thousands until December 2025; year-to-date net income attributed to stockholders of the company was $1,561,524 thousands; EPS is $6.28. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||